Naples, Italy

Aldo Di Vito

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Bracco Imaging S.p.a.. Active years: 2025.


% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aldo Di Vito: Innovator in Diagnostic and Therapeutic Applications

Introduction

Aldo Di Vito is a notable inventor based in Naples, Italy. He has made significant contributions to the field of medical diagnostics and therapeutics. His work focuses on the development of innovative solutions that enhance the understanding and treatment of diseases.

Latest Patents

Aldo Di Vito holds a patent for "CA-IX aptamers and diagnostic and therapeutic uses thereof." This invention provides nucleic acid aptamers that bind to the Carbonic Anhydrase IX (CA-IX) enzyme. The patent outlines derivatives and conjugates of these aptamers and their applications as diagnostic tools. Specifically, they are used for imaging organs and tissues that express CA-IX, as well as therapeutic agents for the prevention or treatment of CA-IX related diseases. He has 1 patent to his name.

Career Highlights

Aldo Di Vito is associated with Bracco Imaging S.p.A., a company known for its advancements in medical imaging. His role at the company has allowed him to contribute to innovative projects that aim to improve patient outcomes through enhanced diagnostic techniques.

Collaborations

Throughout his career, Aldo has collaborated with esteemed colleagues such as Vittorio De Franciscis and Carla Lucia Esposito. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Aldo Di Vito is a prominent figure in the field of medical innovation, particularly in the development of diagnostic and therapeutic applications. His contributions continue to impact the medical community positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…